SCHEMBL7659353

SCHEMBL7659353

Cc1ccc2c(c1)NC(=O)c1cc(C)sc1O2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 1/20 0.47
CSNK1G1 Q9HCP0 1/20 0.42
POLB P06746 2/20 0.41
ROS1 P08922 1/20 0.41
CDK5 Q00535 1/20 0.41
ACVR1 Q04771 1/20 0.41
LRRK2 Q5S007 1/20 0.41
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
MAPT P10636 3/20 0.38
TP53 P04637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 3/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GAA P10253 2/20 0.38
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7658309 0.89 ALDH1A1 (0.46) MMP12CSNK1G1POLBROS1CDK5
SCHEMBL7664938 0.86 CES1 (0.42) POLBLRRK2MAPTTP53LMNA
SCHEMBL7660369 0.86 TGM2 (0.37) LRRK2ACE2ABL1JUNNFKB1
SCHEMBL7658523 0.84 MAPT (0.47) CSNK1G1POLBROS1CDK5ACVR1
Dimethylamine SCHEMBL7666545 0.81 MAPT (0.44) CSNK1G1POLBROS1CDK5ACVR1
SCHEMBL13997687 0.79 ROS1 (0.51) MMP12CSNK1G1POLBROS1CDK5
SCHEMBL7666555 0.78 KMT2A (0.37) ROS1CDK5ACVR1LRRK2MAPT
SCHEMBL7661672 0.78 CES1 (0.42) LRRK2MAPTTP53ALDH1A1RAB9A
SCHEMBL7658287 0.76 ALDH1A1 (0.47) POLBLRRK2MAPTTP53TDP1
SCHEMBL11461762 0.75 MMP12 (0.44) MMP12CSNK1G1POLBROS1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MMP12 916/4885CSNK1G1 1141/4885POLB 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.